Integrated DNA Technologies Adds MLL Munich Leukemia Laboratory to Align Program

The MLL Munich Leukemia Laboratory has a new collaboration partner: Following the launch of the xGen™ NGS portfolio from global genomics solutions provider Integrated DNA Technologies (IDT), MLL has joined the Align program. As the first European partner in the program, MLL and IDT aim to jointly advance genomics research.

The Munich-based leukemia lab's extensive experience in sequencing exomes, genomes and transcriptomes and IDT's robust xGen portfolio of NGS solutions, including library preparation, hybridization and amplicon sequencing, will enable it to support researchers' and scientists' NGS workflow more efficiently in the future.

“We are very pleased to be part of IDT’s Align Program as its first partner in Europe,” said Manja Meggendorfer, head of molecular genetics at MLL. “Partnering with IDT to advance genomics research was an easy decision, as the company’s work uniquely aligns with our mission. As whole exome sequencing, RNA sequencing, and oncology translational research continue to grow in demand, we are excited to work alongside IDT to deliver the sequencing needs of the scientific community and look forward to the new discoveries to come.”

For key information and details on the new collaboration between MLL Munich Leukemia Laboratory and IDT Integrated DNA Technologies, download the official press release.

IDT Integrated DNA Technologies
Kristina Sarenas
Manager of PR
800-328-2661 (USA & Canada)
+1 319-626-8400 (outside USA)
idtpr@idtdna.com

MLL Munich Leukemia Laboratory
Sarah Gallinger
Head of Corporate Communications
+49 89 99017-547
presse@mll.com